LEI:
549300Q7EXQQH6KF7Z84
11 July
2024
RTW Biotech Opportunities
Ltd
Baroness Nicola Blackwood
Appointed as Independent Non-Executive Director
RTW Biotech Opportunities Ltd (the
"Company"), a London Stock Exchange-listed investment company
focused on identifying transformative assets with high growth
potential across the life sciences sector, announces that Baroness
Nicola Blackwood has been appointed to the Company's Board of
Directors as an independent, Non-Executive Director, effective the
11th of July 2024.
Nicola is a leader in science and
entrepreneurship. She is a member of the House of Lords, and Chair
of Genomics England and Oxford University Innovation. Since 2023,
she has been a Supervisory Board member of the biotechnology
company, BioNTech. Nicola served as Minister for Innovation in the
Department for Health and Social Care under two Prime Ministers
where she led on Lifesciences, NHS Data and Digital Transformation,
and Global Health Security. She was the first female MP for Oxford
and was elected by MPs of all parties to Chair the Commons Science
and Tech Committee. She remains one of the youngest committee
chairs in British history and the only woman to have chaired the
Commons Science & Tech Committee.
Bill Scott, Chair of the Nomination
and Remuneration Committee, who led the appointment process said,
"We are delighted to welcome Baroness Blackwood to the board of RTW
Biotech Opportunities Ltd. Nicola brings with her a
remarkable blend of skills and experience, having operated at the
highest levels of government and leadership roles in the
facilitation of fundamental research and strategic
commercialisation of promising innovation in life sciences both in
the UK and overseas. We look forward to working with her to
take RTW Biotech Opportunities to the next level as the leading
investment fund in its sector on the London market and in further
advancing the UK and European biotech ecosystem."
William Simpson, Chair of the Board,
said, "Nicola's involvement in science and technology, within and
outside of government, provides us with significant additional
knowledge from which we all will benefit. The performance of
the Company since inception has been excellent and Nicola's
contribution will help us further develop our mission to harness
innovation in biotech to the advantage of patients and
shareholders."
Nicola Blackwood said, "I am
delighted to be joining the RTW Biotech Opportunities Ltd Board.
Life sciences and innovation will be central in tackling many of
the global challenges we face today. I look forward to engaging
with the RTW team and playing a part in powering innovations from
breakthrough to high-growth companies."
No further details are required to
be disclosed under LR 9.6.13
For
Further Information
RTW
Investments, LP
|
+44
20 7959 6361
|
Woody Stileman, Managing Director,
Business Development
Krisha McCune, Director, Investor
Relations
|
biotechopportunities@rtwfunds.com
|
|
|
Buchanan (PR & Communications Adviser)
|
+44
20 7466 5107
|
Charles Ryland
|
|
Henry Wilson
|
|
George Beale
|
|
|
|
Deutsche Numis (Joint Corporate Broker)
|
+44
20 7260 1000
|
Freddie Barnfield
|
|
Nathan Brown
|
|
Euan Brown
|
|
|
|
BofA Securities (Joint Corporate Broker)
|
+44
20 7628 1000
|
Edward Peel
|
|
Alex Penney
|
|
Cadarn Capital (Distribution & IR
Partner)
|
+44
73 6888 3211
|
David Harris
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief
Executive Officer
Sadie Morrison, Managing
Director
|
+44
14 8181 0100
|
Morgan Stanley Fund Services USA LLC
|
+1
914 225 8885
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW & RTWG) is an investment fund focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a
long-term approach to support innovative businesses, RTW Biotech
Opportunities Ltd invests in companies developing next-generation
therapies and technologies that can significantly improve patients'
lives. RTW Biotech Opportunities Ltd is managed by RTW Investments,
LP, a leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.
***********
The information in this announcement
may include forward-looking statements, which are based on the
current expectations and projections about future events, and in
certain cases can be identified by the use of terms such as "may",
"will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives
thereon) or other variations thereon or comparable terminology.
These forward-looking statements, as well as those included in any
related materials, are subject to risks, uncertainties and
assumptions about the Company and/or its underlying investments,
including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use
of financing proceeds and future capital expenditures and
acquisitions. In light of these risks, uncertainties and
assumptions, the events in the forward-looking statements may not
occur.
The information contained in this
announcement is given at the date of its publication (unless
otherwise marked). No reliance may be placed for any purpose
whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or
fairness.
***********